Page 34 - Expanded Access Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

RedHill Biopharma Announces Closing of $6 Million Registered Direct Offering

RedHill Biopharma Ltd. ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has closed its previously announced registered direct offering for the purchase and sale of 1,500,000 of the Company's American.

United kingdomNew yorkUnited statesRedhill biopharmaAdi frishHc wainwright coCompany annual report on formRedhill biopharma ltdCompany expanded access programCorporate business developmentExchange commissionCompany american depositary shares adssHill biopharma announces closingRegistered directAmerican depositary sharesHill biopharma

RedHill Biopharma Announces $6 Million Registered Direct Offering

/PRNewswire/ RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered.

United kingdomNew yorkUnited statesAdi frishRedhill biopharmaExchange commissionCorporate business developmentRedhill biopharma ltdCompany expanded access programCompany annual report on formCompany american depositary shares adssHc wainwright coAmerican depositary sharesHill biopharmaPrivate securities litigation reform actExpanded access program

NRx Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Business Update

Over the past 12 months, the Company reinitiated its psychiatry development program post pandemic, transferred manufacturing of NRX-101 to the US, and.

United statesFrance generalMarion leboyerAndrew nierenbergStephen willardPrnewswire nrx pharmaceuticals incSource nrx pharmaceuticals incProgram in suicidal treatmentPsychiatry divisionNrxp nrx pharmaceuticalsNrx pharmaceuticalsNrx pharmaceuticals incAccess programHarvard medical schoolData safety monitoring boardSuicidal treatment resistant bipolar depression

NRx Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Business Update

NRx Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Business Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

France generalUnited statesAndrew nierenbergMarion leboyerStephen willardNrx pharmaceuticals reports full yearPsychiatry divisionAccess programNrx pharmaceuticalsHarvard medical schoolNrx pharmaceuticals incProgram in suicidal treatmentData safety monitoring boardSuicidal treatment resistant bipolar depressionMedical schoolPharmaceuticals reports full year

NRx Pharmaceuticals Announces Positive Recommendation to Continue Enrollment in the Ongoing Trial of NRX-101 in Patients with Suicidal Treatment-Resistant Bipolar Depression

/PRNewswire/ NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage CNS biopharmaceutical company, today reported.

United statesStephen willardSource nrx pharmaceuticals incPrnewswire nrx pharmaceuticals incNrx pharmaceuticals incAccess programNrxp nrx pharmaceuticalsNrx pharmaceuticalsData safety monitoring boardSevere bipolar depressionSubacute suicidal ideationTreatment resistant bipolarSuicidal treatment resistant bipolar depressionComprehensive breakthrough therapy meetingSpecial protocol agreementTreatment resistant bipolar depression